breast tumors

(Queen's University) A protein activated by certain drugs already approved for treating type II diabetes may slow or stop the spread of breast tumors.

(Brown University) Researchers from Brown University and the University of California have shown that the epigenetic profiles of breast tumors are related to patient diet and alcohol use as well as tumor size.

(ECCO-the European CanCer Organisation) The presence of a protein called PARP in tumors can help predict their response to chemotherapy, German researchers will tell the European Breast Cancer Conference on Friday, March 26.

They have found that PARP expression exists across all breast cancer subtypes, and that these tumors are highly sensitive to chemotherapy.

PARP positive tumors could become a new entity in breast cancer, and the researchers believe that they may be on the verge of a major change in the way breast cancer is treated.

Freezing a malignant tumor not only kills it, but may also stop the cancer from spreading, according to new research on mice.

(Loyola University Health System) A new study is providing insight into how estrogen fuels many breast cancers, and researchers say the findings could lead to new cancer-fighting drugs.

(Scott & White Healthcare) A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice.

This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back.

(Thomas Jefferson University) Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy.

The findings were published online ahead of print in the Journal of Nuclear Medicine.

(Dana-Farber Cancer Institute) A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

(Dartmouth Medical School) At the end of a 10-year, coast-to-coast study of women with an unusual form of breast cancer, Richard J.

Barth Jr., M.D., and three fellow researchers are making the case for a particular combination of treatments to stop the tumors in their tracks.

MRI technology may be better than mammography at picking up breast tumors, but studies show using it doesn't mean better survival or less tumor recurrence for breast cancer patients